Overview

Spesolimab in Pyoderma Gangrenosum

Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma gangrenosum. Pyoderma gangrenosum is a rare, inflammatory, autoimmune condition which results in ulceration of skin. The study will also investigate the body's immune response to the spesolimab (when the body detects and defends itself against substances that appear unknown and harmful).
Phase:
Phase 2
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborator:
Boehringer Ingelheim